Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Depreciation & Amortization (CF) (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 23.8% to $6.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $25.2 million, a 14.9% increase, with the full-year FY2025 number at $25.2 million, up 14.9% from a year prior.
  • Depreciation & Amortization (CF) was $6.9 million for Q4 2025 at GeneDx Holdings, up from $6.5 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $34.0 million in Q4 2022 to a low of $4.9 million in Q1 2021.
  • A 5-year average of $8.1 million and a median of $6.0 million in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 487.4% in 2022, then crashed 82.1% in 2023.
  • GeneDx Holdings' Depreciation & Amortization (CF) stood at $5.8 million in 2021, then surged by 487.4% to $34.0 million in 2022, then plummeted by 82.1% to $6.1 million in 2023, then dropped by 8.8% to $5.6 million in 2024, then rose by 23.8% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Depreciation & Amortization (CF) are $6.9 million (Q4 2025), $6.5 million (Q3 2025), and $6.2 million (Q2 2025).